The European Medicines Agency said on Tuesday that if its experts have received enough data from drugmakers Pfizer and Moderna about their candidate vaccines against the coronavirus, the agency would complete its reviews by Dec. 29 and Jan. 12, respectively, at latest.
A logo for Pfizer is displayed on a monitor on the floor at the New York Stock Exchange in New York, US. (File photo: Reuters)
Vaccine trial participant David Rach is prepared to test coronavirus disease (COVID-19) vaccine candidate BNT162b2, developed by Pfizer and BioNTech, at the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine in Baltimore on May 24, 2020. (Reuters)